News >

PACIFIC Trial Paves Way for More Immunotherapy Advances in Stage III NSCLC

Jessica Hergert
Published: Thursday, Oct 17, 2019

Anna Chalmers, MD, a clinical instructor in the Division of Oncology and an investigator at Huntsman Cancer Institute, University of Utah

Anna Chalmers, MD

The non–small cell lung cancer (NSCLC) paradigm is evolving as researchers look to build on the momentum of the phase III PACIFIC trial, in which durvalumab (Imfinzi) improved survival in patients with stage III disease, said Anna Chalmers, MD. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication